Integrative Cardiometabolic Care Overview for Obesity

Discover the importance of integrative obesity and cardiometabolic care in managing health and improving lifestyle choices effectively.

Abstract

I am Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST. In this comprehensive educational post, I guide you through an easy-to-follow journey into midlife health for adults ages 40 to 60, focusing on the interconnected web of obesity, cardiometabolic disease, insulin resistance, metabolic liver disease, sleep apnea, musculoskeletal pain, depression, and the unique physiology of menopause. I translate modern, evidence-based research from leading investigators into practical strategies and explain exactly why each technique works, from nutrition and resistance training to advanced pharmacotherapy such as GLP-1 and GIP/GLP-1 agonists. I also show how integrative chiropractic care strengthens outcomes by improving mobility, reducing pain, and enabling sustainable activity. This article highlights how our multidisciplinary team at Injury Medical Clinic PA (also known as Mission Plaza Injury Medical Clinic) in El Paso, Texas, integrates chiropractic, functional medicine, rehabilitation, and internal medicine under the medical direction of Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), an internist with over 40 years of experience. Together, we present a modern model of obesity care that targets adiposity while preserving muscle mass, reducing cardiovascular risk, and improving quality of life.

About Our Integrative Clinic Team In El Paso, Texas

Our collaborative model

I practice at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas. Our care model blends multiple disciplines into a single, coordinated plan:

• Chiropractic care and integrative functional medicine (Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST)
• Internal medicine oversight (Dr. Maria Guadalupe Cardenas, MD; Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933)
• Personal injury and rehabilitation services
• Nutritional counseling and health coaching
• Advanced diagnostics and cardiometabolic risk stratification

The role of medical direction in a multidisciplinary clinic

• Cardenas serves as our Medical Director and Collaborative Physician. With more than 40 years as an internist, she ensures our interventions align with best evidence, regulatory standards, and patient safety.
• This team structure is common in integrative injury and wellness clinics where a licensed MD provides medical oversight and collaborates directly with chiropractic and rehabilitative services.
• The integration allows us to safely implement anti-obesity medications, manage complex comorbidities (hypertension, diabetes, dyslipidemia), and combine them with chiropractic and functional approaches that enhance mobility, reduce pain, and sustain behavior change.

How chiropractic integrates into metabolic care

• Chiropractic adjustments address biomechanical stress, spinal and extremity joint dysfunction, and neuromuscular imbalances that accumulate with excess body weight.
• By restoring motion and reducing pain, patients can perform the aerobic and resistance training required to preserve lean mass during weight loss.
• Integrated chiropractic care reduces the pain-inactivity-weight gain cycle, enabling adherence to nutrition, activity, and sleep plans that restore insulin sensitivity and cardiometabolic stability.

Why Treating Obesity in Midlife Requires An Integrative, Systems Approach

Our core goals of modern obesity treatment

• Reduce adiposity, not just weight, while preserving or building lean muscle mass.
• Prevent and mitigate obesity-related complications such as type 2 diabetes, hypertension, dyslipidemia, sleep apnea, MASLD (metabolic dysfunction-associated steatotic liver disease), and heart failure.
• Improve day-to-day function, mobility, and quality of life.

Even a 5% to 10% reduction in body weight produces meaningful improvements in blood pressure, glycemic control, liver fat, sleep apnea measures, knee osteoarthritis pain, and overall energy and mood (Ryan & Yockey, 2017). Sustained losses of 10%–15% and beyond deliver even larger benefits.

Why integrated care is essential

• Obesity is not an isolated “calories in vs. calories out” issue; it is a whole-body disorder involving adipose-derived inflammation, insulin resistance, hormonal disruption, neurohormonal dysregulation, circadian and sleep interference, and biomechanical overload.
• Single-modality care is inadequate. The best outcomes emerge when we combine medical, chiropractic, rehabilitative, functional nutrition, sleep optimization, and behavioral interventions into a coordinated plan.

Cardiometabolic Syndrome In Midlife: Understanding The Vicious Cycle

What is cardiometabolic syndrome?

Cardiometabolic syndrome (metabolic syndrome) is a cluster of risk factors tightly linked to excess adiposity and insulin resistance:

• Dyslipidemia (high triglycerides, low HDL, increased atherogenic ApoB particle number)
• Hypertension
• Dysglycemia (prediabetes or type 2 diabetes)
• Increased abdominal waist circumference, a proxy for visceral fat

The pathophysiology centers on dysfunctional adipose tissue, especially visceral fat, which releases inflammatory cytokines and free fatty acids that:

• Drive systemic and hepatic insulin resistance
• Promote endothelial dysfunction and vasoconstriction, elevating blood pressure
• Increase atherogenic lipoproteins and plaque formation

The prevalence of metabolic syndrome approaches one in three adults. In my clinic, measuring waist circumference is non-negotiable because it correlates closely with visceral fat burden and cardiometabolic risk.

Our integrative cardiometabolic risk assessment

• Vital signs: blood pressure and home BP logs; waist circumference for central adiposity.
• Body composition: InBody or DEXA to quantify fat mass, visceral adipose tissue, and lean mass.
• Laboratory panel:

• • Fasting lipid panel with triglycerides, HDL, LDL
  • Advanced markers: Apolipoprotein B (ApoB), Lipoprotein(a) [Lp(a)]
  • Glycemic status: fasting glucose, HbA1c, fasting insulin
  • Inflammation: high-sensitivity C-reactive protein (hs-CRP)

• For selected patients: coronary artery calcium (CAC) scoring.
• Psychosocial screening: stress, depression, sleep quality, and social support.

Chiropractic assessment identifies mobility restrictions, joint overload, and myofascial pain patterns that reinforce inactivity and metabolic decline.

Obesity And Cardiovascular Disease: Why Treating Fat Mass Treats The Heart

The hemodynamic, inflammatory, and neurohormonal burden

Obesity increases blood volume and cardiac output, stiffens vessels, drives RAAS activation and sympathetic tone, and injects inflammatory signaling into the endothelium. These pathways converge on plaque formation, vascular dysfunction, and structural heart adaptations such as left ventricular hypertrophy.

The danger of”sick fat” around the heart

• Pericardial and epicardial adipose tissue are metabolically active depots adjacent to the myocardium and coronary arteries.
• They mechanically stiffen the heart, promoting diastolic dysfunction and HFpEF (heart failure with preserved ejection fraction).
• They locally secrete cytokines that accelerate atherosclerosis and can contribute to arrhythmias, including atrial fibrillation.

Landmark evidence that treating obesity lowers cardiac events

• The SELECT trial demonstrated that once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults over 45 with BMI ≥27 and established cardiovascular disease without diabetes (compared with placebo) (Wilding et al., 2021; Marso et al., 2016). This provides powerful evidence that treating obesity itself reduces cardiovascular risk.

Heart Failure Prevention In Midlife: Identifying Stage A And Intervening Early

Stage A heart failure.

• Defined as”at risk” for heart failure without structural disease. Patients with obesity, hypertension, diabetes, and dyslipidemia fall into this category.
• This is the prime prevention window to avert symptomatic heart failure.

Our four-pillar prevention plan

1. Nutrition therapy

• • Emphasize anti-inflammatory, heart-healthy patterns such as DASH and Mediterranean-style eating that are rich in vegetables, fruits, legumes, whole grains, lean proteins, and olive oil, and low in sodium, added sugars, and ultra-processed foods.

• Physical activity

• • Aim for at least 150 minutes of moderate-intensity exercise per week.
  • Use chiropractic adjustments and rehab strategies to reduce barriers to movement (pain, stiffness, poor joint mechanics).

• Sleep optimization

• • Target 7–8 hours of restorative sleep; screen and treat sleep apnea.

• Pharmacotherapy and risk factor optimization

• • Weight reduction goal: at least 10% to 15% total body weight to “unload” the heart, improve insulin sensitivity, and reduce visceral fat.
  • Optimize BP and glucose management; consider anti-obesity medications (AOMs) when indicated.

New evidence for symptom improvement in established HFpEF

• STEP-HFpEF showed semaglutide improved symptoms, functional status, and weight in obesity-related HFpEF.
• SUMMIT demonstrated that tirzepatide reduced the composite of cardiovascular death or worsening heart failure and improved health status in patients with obesity and HFpEF.

These trials support a therapeutic paradigm: treat obesity to treat heart failure outcomes and symptoms.

Dyslipidemia In Obesity: Targeting Atherogenic Particles And Triglycerides

Atherogenic dyslipidemia

• Elevated triglycerides
• Low HDL-C
• Increased small, dense LDL particles
• Elevated ApoB as a direct count of atherogenic particles

Our approach

• Weight reduction of 5%–15% reduces triglycerides and ApoB while increasing HDL.
• Emphasize Mediterranean-style nutrition with high fiber and healthy fats, coupled with consistent physical activity to raise HDL.
• Start statins per ASCVD risk; consider AOMs to reduce adiposity and remodel the lipid profile at its source.

Hypertension And Obesity: Mechanisms And Measurable Improvements

Why obesity elevates blood pressure

• Mechanical compression of kidneys and arterioles increases peripheral resistance.
• Adipose-driven inflammation damages endothelium, increasing vasoconstriction.
• RAAS activation promotes sodium retention and vascular constriction.

Impact of weight loss

• Losing 3%–9% of body weight lowers systolic and diastolic pressures by about 3 mmHg on average; losing 10%–15% often delivers larger improvements and may allow de-prescribing antihypertensives.
• DASH diet remains a cornerstone; teach home BP monitoring to guide safe medication adjustment as weight drops.

Insulin Resistance: The Central Hub Connecting Adiposity And Disease

The physiology of insulin resistance

• Enlarged, inflamed adipocytes leak free fatty acids and release cytokines that impair insulin signaling in liver, muscle, and vascular tissues.
• Chronic hyperinsulinemia locks the body into storage mode, inhibits lipolysis, drives hunger and cravings, and creates metabolic inflexibility.

Early identification matters

Key markers we use:

• Fasting insulin (optimal typically below ~5–8 µIU/mL in many patients)
• Fasting glucose and HbA1c
• HOMA-IR using fasting insulin and glucose
• Triglyceride-to-HDL ratio as a proxy for insulin resistance
• Clinical context: visceral adiposity, family history, and lifestyle

Evidence from population-level analyses shows insulin resistance elevates cardiovascular mortality risk at younger ages than expected, reinforcing the urgency of early treatment.

Breaking the cycle

• Nutrition strategies that control postprandial insulin (low-glycemic, lower-carbohydrate patterns) support fat mobilization and improve satiety.
• Resistance training increases skeletal muscle mass and GLUT4-mediated glucose uptake.
• Sleep and stress management reduce counterregulatory hormones that worsen glycemia.
• Off-label metformin may be considered under medical supervision for insulin resistance, alongside indicated AOMs.

Prediabetes And Type 2 Diabetes: Treat Obesity To Reverse Glycemic Trajectories

The evidence for weight-first strategies

• Look AHEAD showed durable weight loss reduced the need for medications across glycemia, lipids, and blood pressure.
• Even 2%–5% weight loss can reduce fasting glucose by about 20 mg/dL.
• Modern incretin therapies (GLP-1 and GIP/GLP-1 agonists) significantly improve glycemic control and facilitate clinically meaningful weight loss.

Groundbreaking trials

• SURMOUNT-1: Tirzepatide reduced progression to type 2 diabetes by 94% over three years in participants with obesity and prediabetes, with average weight loss near 23% at higher doses (Jastreboff et al., 2022).
• STEP 1: Semaglutide delivered average weight loss near 14%, with 81% achieving normoglycemia.

These studies show that aggressive, evidence-based obesity treatment can prevent diabetes onset and reverse dysglycemia.

MASLD And MASH: The Liver As A Metabolic Barometer

A new name with a clearer cause

• MASLD (formerly NAFLD) and MASH (formerly NASH) reflect metabolic dysfunction as the root cause.
• More than two-thirds of MASLD patients have obesity.

Screening and stratification

• ALT typically exceeds AST in MASLD; monitor at-risk patients every 2–3 years.T he
• FIB-4 score, using age, AST, ALT, and platelets, identifies fibrosis risk and the need for further evaluation (e.g., FibroScan).
• Always exclude other causes: alcohol excess, viral hepatitis, and hepatotoxic medications.

Treatment goals

• Weight loss of 10% or more reduces liver fat and inflammation and can regress early fibrosis.
• Mediterranean-style nutrition with low ultra-processed intake; combine with both aerobic and resistance training.
• Consider vitamin E in specific MASH cases, GLP-1 or GIP/GLP-1 agonists for weight-driven improvements, and resmetirom for F2–F3 fibrosis per hepatology protocols.

Chronic Stress, Depression, And Weight Bias: The Hidden Drivers Of Relapse

Stress physiology and food choices

• Chronic stress alters hypothalamic regulation of hunger and satiety, elevates ghrelin, impairs executive control in the prefrontal cortex, and amplifies reward pathways—driving cravings for hyper-palatable foods.
• Depression co-occurs frequently with obesity and is associated with higher prevalence and severity, especially in women.

Weight bias in healthcare and society

• Many patients avoid care after stigmatizing encounters.
• We center empathy and active listening to ensure patients feel seen, not blamed.
• Reducing weight bias is essential for engagement, adherence, and mental health.

Therapeutic strategies

• Start with achievable weight loss of 5%–10% to improve mood, mobility, and pain.
• Emphasize sleep, minimally processed nutrition, and joyful movement.
• Encourage therapy and peer support; use antidepressants appropriately when indicated.

Musculoskeletal Pain, Osteoarthritis, And Mobility: Biomechanics Meets Metabolism

The dual burden on joints

• Excess mass multiplies joint loads: approximately 3x body weight across the knee during walking, 6x on stairs, and up to 10x during jumping.
• Adipose-driven inflammation accelerates cartilage breakdown and synovial irritation.

Chiropractic care as a mobility enabler

• Adjustments restore joint mechanics, reduce nociceptive input, and normalize neuromuscular recruitment patterns.
• Improved spinal and extremity function reduces pain, expands range of motion, and allows the reintroduction of aerobic and resistance training.

Clinical tools

• Functional tests such as timed “Get Up and Go” identify mobility and balance deficits.
• Imaging as indicated clarifies osteoarthritic changes and guides rehab.

Integrating pharmacotherapy

• STEP 9 showed semaglutide reduced knee osteoarthritis pain and body weight, reinforcing weight-first strategies to reduce biomechanical loading and inflammatory signaling.

Obstructive Sleep Apnea In Obesity: A Disease Of Fat Mass And Collapsibility

Anatomy and physiology

• Fat deposition in the upper airway soft tissues and tongue increases collapsibility; larger neck circumference elevates risk.
• OSA fragments sleep, activates stress pathways, worsens insulin resistance, and increases hunger—fueling a vicious metabolic cycle.

Screening and diagnosis

• STOP-BANG and Epworth Sleepiness Scale in clinic.
• Polysomnography to confirm severity via AHI:

• • Mild: 5–15
  • Moderate: 15–30
  • Severe: >30

Treatment pathway

• Weight reduction of 5%–15% significantly improves AHI; some mild cases resolve.
• CPAP remains frontline therapy for moderate-to-severe OSA.
• SURMOUNT-OSA: Tirzepatide significantly reduced OSA severity in adults with obesity, leading to the 2024 FDA indication for moderate-to-severe OSA in this population (Malhotra et al., 2024).

The Modern Evidence Landscape: How Trials Inform Practice

Selected conditions and pivotal studies we integrate into care planning:

• Cardiovascular disease and HFpEF: SELECT, STEP-HFpEF, SUMMIT
• Obstructive sleep apnea: SURMOUNT-OSA
• Osteoarthritis: STEP 9
• Prediabetes and diabetes prevention: SURMOUNT-1, STEP 1
• CKD: FLOW
• Liver disease: emerging tirzepatide and semaglutide data; resmetirom for MASH F2–F3

These trials underpin a unifying theme: treat obesity to improve or resolve multiple comorbidities.

Case Study 1: Robert’s Three-Year Transformation With Integrated Care

Robert at baseline

• Age: 55
• BMI: 40.6 kg/m² (275 lbs)
• Waist: 43 in
• Blood pressure: 148/92 mmHg
• HbA1c: 8.5%
• Fasting glucose: 180 mg/dL
• Lipids: triglycerides 250 mg/dL, HDL 35 mg/dL, LDL 140 mg/dL
• Liver enzymes: AST 55 U/L / ALT 68 U/L (consistent with MASLD)
• STOP-BANG: 6 (high OSA risk)
• PHQ-9: 9 (mild depression)
• Medications: metformin, glipizide, lisinopril, rosuvastatin
• Primary issues: knee osteoarthritis pain, daytime fatigue, inconsistent CPAP

Integrative plan

• Nutrition: low-glycemic, high-protein, high-fiber focus to reduce insulin demand and support satiety and muscle preservation.
• Physical activity: begin with non-impact cardio (swimming, cycling) and progressively add resistance training; chiropractic adjustments to improve joint mechanics and reduce pain.
• Pharmacotherapy:

• • Transition off glipizide to avoid hypoglycemia and weight gain.
  • Initiate tirzepatide at 2.5 mg weekly and titrate upward over months as tolerated, maintaining metformin.

• Sleep: improve CPAP adherence; address sleep hygiene.
• Behavioral support: set realistic targets (first 10% weight loss), celebrate milestones, and reinforce consistency.

The results after three years

• Weight dropped from 275 to 200 lbs (−75 lbs; −27.3% TBWL; BMI from 40.6 to 29.3).
• HbA1c moved into the prediabetes range and remained stable.
• Triglycerides decreased markedly; HDL rose; blood pressure normalized with the potential to reduce medications.
• Mobility improved; knee pain decreased with weight loss, exercise, and chiropractic care.
• Quality of life and energy increased, and libido concerns were reframed in the context of microvascular repair as glycemia and BP improved.

Key lesson: combining modern incretin therapy with chiropractic-enabled mobility, resistance training, and targeted nutrition delivers durable, surgical-level weight loss and cardiometabolic restoration.

Part 2: Menopause, Weight, And Metabolic Health — An Integrative Roadmap

Why menopause is a metabolic event

• Falling estrogen alters fat distribution from gynoid to android, increasing visceral fat and waist circumference.
• Simultaneous declines in lean mass (sarcopenia) and bone density elevate risks for insulin resistance, dyslipidemia, hypertension, cardiovascular disease, osteoporosis, and frailty.
• Vasomotor symptoms (VMS) often precede metabolic deterioration; higher BMI and larger waists exacerbate hot flashes and night sweats. Weight loss reduces VMS frequency and severity (Thurston et al., 2019).

Our treatment goals for menopausal transition

• Prevent further weight gain and reduce adiposity while preserving or building lean mass.
• Restore insulin sensitivity and cardiometabolic markers.
• Improve sleep, mood, and quality of life.
• Support bone and muscle health with resistance training and adequate protein.

Nutrition: the power of protein in anabolic resistance

• Menopausal muscle becomes less responsive to anabolic signals; women often require 30–40 g of high-quality protein per meal to trigger muscle protein synthesis (MPS).
• Total daily target: approximately 1.2–1.6 g/kg of ideal body weight, distributed across meals and snacks.
• Whey protein supplementation (rich in leucine) can help achieve per-meal thresholds conveniently; vitamin D sufficiency supports muscle and bone.
• Emphasize fiber-rich vegetables and fruits for satiety, gut health, and glycemic control; minimize ultra-processed foods.

Physical activity for muscle, bone, and metabolism

• Resistance training is the cornerstone for combating sarcopenia, boosting basal metabolic rate, and improving insulin sensitivity.
• Combine weight-bearing activity and HIIT where appropriate to enhance bone density, cardiovascular fitness, and glucose disposal.
• Chiropractic adjustments reduce barriers to consistent training by improving joint function and decreasing pain.

Pharmacotherapy considerations

• Review medications that promote weight gain (some antidepressants, sedatives) and choose weight-neutral or weight-negative alternatives when possible.
• Consider anti-obesity medications for BMI ≥30 or ≥27 with comorbidities to reduce hunger and improve adherence.
• Menopausal hormone therapy (MHT) may be appropriate for VMS and can favorably influence insulin sensitivity and body composition in carefully selected candidates.
• As always, coordinate with internal medicine oversight to ensure safety and align with guidelines.

Part 3: Sarcopenic Obesity — The Hidden Phenotype Driving Risk And Treatment Dropout

What is sarcopenic obesity?

• A dual condition of increased fat mass and reduced muscle mass/strength that worsens metabolic and functional outcomes.
• Inflammation from adipose tissue accelerates muscle catabolism; reduced muscle lowers resting energy expenditure, driving further fat gain in a vicious cycle.

Prevalence and risk groups

• Present in almost 8% of adults ages 20–60; over 28% beyond 60.
• High rates in Mexican American women over 60 and in populations with prediabetes, type 2 diabetes, MASLD, and post-bariatric surgery.

How weight cycling worsens sarcopenic obesity

• Aggressive dieting without adequate protein and resistance training leads to disproportionate muscle loss.
• Weight regain after dieting preferentially restores fat, not muscle, degrading body composition with each cycle and increasing dropout rates in future programs.

Assessment

• Functional tests: grip strength, sit-to-stand performance.
• Body composition: BIA scales and DEXA scans to quantify fat, visceral adipose tissue, and regional lean mass.

Treatment strategy

• Nutrition: 1.0–1.5 g/kg ideal body weight of protein, evenly spaced; prioritize high-leucine animal proteins and whey supplementation; high-fiber produce; reduce refined carbohydrates to lower insulin demand.
• Exercise: two or more weekly resistance training sessions plus guideline-concordant cardio.
• PT referral: essential for safe, progressive resistance training, especially with comorbid musculoskeletal limitations.
• Chiropractic care: align joints, improve neuromuscular efficiency, reduce pain, and enable progressive overload with lower injury risk.

Case Study 2: Maggie — Perimenopause, Prediabetes, And Early Obesity

Baseline profile and trend

• Age: 53; high-stress career; caring for teens and an aging parent.
• Over three years: weight rose from 135 to 154 lbs; BMI from 22.5 to 27.5; waist from 33 to 37.5 inches.
• HbA1c increased to 5.8% (prediabetes); fasting insulin 11.7 µU/mL indicates insulin resistance; LDL-C 128 mg/dL.
• On levothyroxine; gabapentin 300 mg BID for hot flashes/insomnia; nightly wine habit.

Diagnoses

• Overweight/early obesity with abdominal adiposity
• Prediabetes with insulin resistance and strong family history
• Elevated LDL-C
• Perimenopausal symptoms

Integrated plan

• Nutrition: low-carbohydrate, high-protein; 90–100 g protein/day; significant protein every 3–4 hours; 50–100 g daily of non-starchy vegetables and low-glycemic fruits; reduce processed carbohydrates; collaboratively reduce nightly wine to improve sleep and insulin sensitivity.
• Physical activity: add structured brisk walks or cardio sessions in addition to dog walks; begin one full-body resistance session per week and progress.
• Sleep and VMS: reassessgabapentin’ss effectiveness; if inadequate, consider MHT after evaluating candidacy; improve sleep hygiene and consider CBT-I.
• Metabolic therapy: initiate metformin ER 500 mg daily off-label for insulin resistance; titrate slowly; consider AOMs if lifestyle plus metformin is insufficient.

Key message: recognize early metabolic decline during perimenopause, intervene comprehensively, and measure progress objectively.

Case Study 3: Maria — Sarcopenic Obesity With Established Chronic Disease

Baseline profile

• Age: 59; prior myocardial infarction three years ago.
• Type 2 diabetes x 10 years (HbA1c 7.4%); hypertension and dyslipidemia; MASLD; severe bilateral knee osteoarthritis.
• BMI: 35.7; DEXA: body fat 57.8%, visceral adipose 3.4 L, muscle mass 4th percentile; triglycerides 256 mg/dL; HDL 37 mg/dL; waist 43.5 in.
• On metformin, insulin, lisinopril, amlodipine, rosuvastatin, diclofenac.

Diagnoses

• Class II obesity with sarcopenic phenotype
• Type 2 diabetes, not at target
• Dyslipidemia with hypertriglyceridemia
• MASLD
• Severe knee osteoarthritis
• Post-MI cardiovascular risk

Integrated plan and advocacy

• Nutrition: low-carbohydrate, high-protein pattern to improve glycemia and triglycerides while building muscle.
• PT referral: for sarcopenia, deconditioning, and knee OA to design a safe, progressive resistance plan.
• Orthopedic evaluation: injections or surgical options may be indicated; address potential bias and support the patient through referrals and decision-making.
• Pharmacotherapy:

• • Initiate a GLP-1 RA (e.g., semaglutide) because of type 2 diabetes and prior MI (MACE risk reduction indication).
  • Taper and ultimately discontinue insulin as glycemic control improves to remove weight-promoting effects.

• Exercise modalities: non-impact cardio (swimming, water aerobics, stationary cycling) guided by PT; begin resistance work 1–2 times per week.
• Chiropractic: joint alignment and neuromuscular optimization reduce pain and enable participation in PT and home programs.

Key message: coordinated, bias-aware advocacy plus modern pharmacology and integrative musculoskeletal care can reverse trajectory even in complex disease.

Putting It All Together: Why This Model Works

The physiology behind success

• Weight reduction driven by lower insulin demand and higher insulin sensitivity reverses the hormonal profile that sustains adiposity.
• Resistance training expands the muscle glucose sink, increases basal metabolic rate, and improves mitochondrial function.
• Chiropractic adjustments and rehabilitative care remove motion barriers, improve proprioception and muscle recruitment, and reduce nociceptive drive that perpetuates sympathetic arousal and sleep fragmentation.
• Sleep optimization balances leptin and ghrelin, stabilizes cortisol, and supports glucose homeostasis.
• Incretin-based pharmacotherapy (GLP-1, GIP/GLP-1) aligns physiology with behavior by reducing hunger, slowing gastric emptying, and enhancing glucose-dependent insulin secretion without driving hypoglycemia.
• Internal medicine oversight ensures safe titration, de-prescribing as metrics improve, and precise risk stratification for cardiovascular and hepatic complications.

Clinical observations from practice

My clinical observations, shared across my platforms, underscore consistent themes:

• Patients move better and commit more fully to activity after chiropractic care reduces pain and stiffness.
• Strategic protein intake throughout the day improves satiety and supports lean mass preservation or gain during calorie deficits.
• Small, achievable goals build durable habits; celebrating early 5%–10% losses boosts morale and delivers measurable cardiometabolic gains.
• Addressing sleep, alcohol patterns, and stress transforms the metabolic environment and reduces relapse risk.

Clinical observations of Dr. Alexander Jimenez, DC, APRN, FNP-BC:

• https://pushasrx.com/
• https://www.linkedin.com/in/dralexjimenez/

Practical Next Steps: How We Start This Journey Together

• Comprehensive intake with vitals, waist measurement, and functional movement screen.
• Labs including fasting insulin, lipid panel with triglycerides and HDL-C, HbA1c, hs-CRP; consider ApoB and Lp(a).
• Body composition via InBody or DEXA (recommended baseline).
• Sleep screening (STOP-BANG, Epworth) and depression screening (PHQ-9).
• Initial plan incorporating:

• • High-protein, high-fiber nutrition with minimized ultra-processed foods
  • Two weekly resistance sessions and progressive non-impact cardio as needed
  • Chiropractic care to restore joint mechanics, plus PT where indicated
  • Sleep and stress optimization
  • Medication review; consider metformin for insulin resistance and AOMs per criteria

• Follow-up cadence and clear milestones: target first 5%–10% weight loss, then step up to 10%–15% and beyond as appropriate.

References

• Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study (Look AHEAD Research Group, 2014). Obesity (Silver Spring), 22(1), 5–13.
• Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding et al., 2021). New England Journal of Medicine, 384(11), 989–1002.
• Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (Marso et al., 2016). New England Journal of Medicine, 375(19), 1834–1844.
• Tirzepatide once weekly for the treatment of obesity (Jastreboff et al., 2022). New England Journal of Medicine, 387(3), 205–216.
• Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (Malhotra et al., 2024). New England Journal of Medicine.
• Weight Loss and Improvement in Comorbidities: Differences at 5%, 10%, 15%, and Over (Ryan & Yockey, 2017). Current Obesity Reports, 6(2), 187–194.
• Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (Wilding et al., 2021). New England Journal of Medicine, 384(11), 989–1002.
• Vasomotor symptoms and sleep in the Study of Women’s Health Across the Nation (Thurston et al., 2019). Menopause, 26(8), 812–818.
• Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: A phase 2 trial (Loomba et al., 2023). The Lancet Gastroenterology & Hepatology, 8(9), 779–789.
• The physical activity guidelines for Americans (Piercy et al., 2018). JAMA, 320(19), 2020–2028.
• Sarcopenia: revised European consensus on definition and diagnosis (Cruz-Jentoft et al., 2019). Age and Aging, 48(1), 16–31.
• Sarcopenic obesity: definition, cause and consequences (Stenholm et al., 2008). Current Opinion in Clinical Nutrition and Metabolic Care, 11(6), 693–700.
• Semaglutide Treatment Effect in People with Obesity and Knee Osteoarthritis (STEP 9). New England Journal of Medicine.
• Tirzepatide in HFpEF with Obesity (SUMMIT). New England Journal of Medicine.
• Semaglutide in HFpEF with Obesity (STEP-HFpEF). New England Journal of Medicine.

Note: Some trial details above are summarized from peer-reviewed publications and major medical journals. Where direct links are not provided, please search the journal title and trial name for the latest access links.

SEO Tags

obesity care, midlife health, cardiometabolic syndrome, insulin resistance, hypertension, dyslipidemia, heart failure with preserved ejection fraction, HFpEF, semaglutide, tirzepatide, GLP-1, GIP GLP-1 dual agonist, sleep apnea, SURMOUNT-OSA, MASLD, MASH, metabolic liver disease, menopause, vasomotor symptoms, sarcopenic obesity, resistance training, high protein diet, DASH diet, Mediterranean diet, chiropractic care, integrative medicine, functional medicine, rehabilitation, El Paso Texas, Injury Medical Clinic, Mission Plaza Injury Medical Clinic, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, ApoB, Lp(a), CAC score, DEXA, body composition, epicardial fat, pericardial fat, STEP trials, SELECT trial, SUMMIT trial, Look AHEAD, endocrinology, lifestyle medicine, quality of life, de-prescribing, musculoskeletal pain, osteoarthritis, personal injury rehabilitation, sleep optimization, stress management, anti-obesity medications, medical oversight, multidisciplinary clinic